BioSpace News Archive

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announces its financial results for the first quarter ended January 31, 2021 and provides a business update.

MannKind Corporation announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 pursuant to the exercise in full of the initial purchasers’ option in connection with MannKind’s previously-announced private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent and new data covering what the Company believes to be the first gene-modified, stem cell derived, universal donor dendritic cell cancer immunotherapy.

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that Health Canada has granted market authorization to Perjeta® (pertuzumab for injection) as a neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive)

Cleveland based GenomOncology and UH Seidman Cancer Center enter into a market-leading partnership to increase clinical trial accrual rates.

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that Gary Shangold, M.D., Chief Medical Officer at Enteris, will host a webinar, titled “The 505(b)(2) Pathway: A Vehicle for Innovation and Product Differentiation,”

ChromaCode, Inc. today announced that the company has been selected as a Main Track Winning Team in the XPRIZE Rapid COVID Testing competition, which aims to increase COVID-19 testing capabilities 100-times past the current standard

Imbio, a leading provider of artificial intelligence (AI) solutions for medical imaging analysis, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RV/LV Analysis™ algorithm

Smile Train, the world’s largest cleft organization, announced the addition of Roberto L. Flores, MD, to its Global Medical Advisory Board.

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, recently revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19